You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Effect of CGRP and sumatriptan on the BOLD response in visual cortex
|
|---|---|
| Published in |
The Journal of Headache and Pain, January 2012
|
| DOI | 10.1007/s10194-011-0415-4 |
| Pubmed ID | |
| Authors |
Mohammad S. Asghar, Adam E. Hansen, Henrik B. W. Larsson, Jes Olesen, Messoud Ashina |
| Abstract |
To test the hypothesis that calcitonin gene-related peptide (CGRP) modulates brain activity, we investigated the effect of intravenous CGRP on brain activity in response to a visual stimulus. In addition, we examined if possible alteration in brain activity was reversed by the anti-migraine drug sumatriptan. Eighteen healthy volunteers were randomly allocated to receive CGRP infusion (1.5 μg/min for 20 min) or placebo. In vivo activity in the visual cortex was recorded before, during and after infusion and after 6 mg subcutaneous sumatriptan by functional magnetic resonance imaging (3 T). 77% of the participants reported headache after CGRP. We found no changes in brain activity after CGRP (P = 0.12) or after placebo (P = 0.41). Sumatriptan did not affect brain activity after CGRP (P = 0.71) or after placebo (P = 0.98). Systemic CGRP or sumatriptan has no direct effects on the BOLD activity in visual cortex. This suggests that in healthy volunteers both CGRP and sumatriptan may exert their actions outside of the blood-brain barrier. |
Mendeley readers
The data shown below were compiled from readership statistics for 60 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 3 | 5% |
| Denmark | 1 | 2% |
| Unknown | 56 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 22% |
| Student > Ph. D. Student | 10 | 17% |
| Student > Bachelor | 9 | 15% |
| Student > Master | 9 | 15% |
| Other | 6 | 10% |
| Other | 8 | 13% |
| Unknown | 5 | 8% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 31 | 52% |
| Psychology | 5 | 8% |
| Neuroscience | 5 | 8% |
| Agricultural and Biological Sciences | 4 | 7% |
| Nursing and Health Professions | 2 | 3% |
| Other | 4 | 7% |
| Unknown | 9 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 January 2023.
All research outputs
#7,866,480
of 23,849,058 outputs
Outputs from The Journal of Headache and Pain
#708
of 1,417 outputs
Outputs of similar age
#72,754
of 248,327 outputs
Outputs of similar age from The Journal of Headache and Pain
#8
of 14 outputs
Altmetric has tracked 23,849,058 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,417 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.6. This one is in the 42nd percentile – i.e., 42% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 248,327 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.